Announcements Trials
Browse Landscape

Phase

Phase 1 1

Status

Completed 1

Sponsor Class

OTHER 1NIH 1

Study Type

Interventional 1

Sponsor

Cancer Type

Genitourinary 1

Conditions

Prostatic Neoplasms 20Prostate Carcinoma Metastatic to the Bone 2Metastatic Castration-resistant Prostate Cancer 2Thyroid Neoplasms 1Prostate Cancer Metastatic to Bone 1Prostate Adenocarcinoma 1Pain 1Neoplasm Metastasis 1Metastatic Castration-resistant Prostate Cancer (mCRPC) 1Lung Neoplasms 1Fatigue 1Carcinoma, Renal Cell 1Carcinoma, Non-Small-Cell Lung 1Breast Neoplasms 1Bony Metastases From Castrate Refractory Prostate Cancer 1Advanced Prostate Cancer 1

Interventions

Nivolumab 74Sunitinib 73pembrolizumab 49Everolimus 39Sorafenib 36Bevacizumab 36Axitinib 36cabozantinib 35Radiosurgery 33Ipilimumab 33pazopanib 32Magnetic Resonance Spectroscopy 27Interleukin-2 27aldesleukin 23Specimen Handling 22Cyclophosphamide 21lenvatinib 20fludarabine phosphate 17Radiotherapy 16Interferon-alpha 15Peripheral Blood Stem Cell Transplantation 14Gemcitabine 14Biopsy 14temsirolimus 13Nephrectomy 13durvalumab 11Immunohistochemistry 11CTLA-4 Antigen 11Blood Specimen Collection 11Capecitabine 10

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
OTHER × Carcinoma, Renal Cell × radium Ra 223 dichloride × Clear all
NCT02406521 2020-03-04

Exploratory Study of Radium-223 and VEGF-Targeted Therapy in Patients With Metastatic Renal Cell Carcinoma and Bone Mets

Dana-Farber Cancer Institute

Phase 1 Completed
30 enrolled
Genitourinary

Carcinoma, Renal Cell

Data powered by HemOnc (CC BY 4.0) Colophon âš¡